U.S. markets close in 3 hours 53 minutes
  • S&P 500

    4,157.93
    +42.25 (+1.03%)
     
  • Dow 30

    34,137.97
    +241.93 (+0.71%)
     
  • Nasdaq

    13,506.92
    +207.18 (+1.56%)
     
  • Russell 2000

    2,201.72
    +8.08 (+0.37%)
     
  • Crude Oil

    63.01
    -0.35 (-0.55%)
     
  • Gold

    1,880.90
    -0.60 (-0.03%)
     
  • Silver

    28.02
    +0.01 (+0.04%)
     
  • EUR/USD

    1.2222
    +0.0040 (+0.33%)
     
  • 10-Yr Bond

    1.6390
    -0.0440 (-2.61%)
     
  • GBP/USD

    1.4177
    +0.0064 (+0.46%)
     
  • USD/JPY

    108.7900
    -0.3790 (-0.35%)
     
  • BTC-USD

    40,231.64
    +3,265.85 (+8.83%)
     
  • CMC Crypto 200

    1,054.10
    +56.88 (+5.70%)
     
  • FTSE 100

    7,019.79
    +69.59 (+1.00%)
     
  • Nikkei 225

    28,098.25
    +53.80 (+0.19%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VRM, KDMN and FGEN

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 20, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Vroom, Inc. (NASDAQ:VRM)

Investors Affected : June 9, 2020 - March 3, 2021

A class action has commenced on behalf of certain shareholders in Vroom, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Vroom had not demonstrated that it was able to control and scale growth in respect to its salesforce to meet the demand for its products; (2) as a result, the Company was forced to discount aged inventory to move through its retail channels or liquidated in its wholesale channels; (3) as a result, the ecommerce gross profit per unit was reasonably likely to decline; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/vroom-inc-loss-submission-form/?id=15970&from=1

Kadmon Holdings, Inc. (NASDAQ:KDMN)

Investors Affected : October 1, 2020 - March 10, 2021

A class action has commenced on behalf of certain shareholders in Kadmon Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/kadmon-holdings-inc-loss-submission-form/?id=15970&from=1

FibroGen, Inc. (NASDAQ:FGEN)

Investors Affected : October 18, 2017 - April 6, 2021

A class action has commenced on behalf of certain shareholders in FibroGen, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=15970&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/648366/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-VRM-KDMN-and-FGEN